Research programme: ZW 34 - Zymeworks

Drug Profile

Research programme: ZW 34 - Zymeworks

Alternative Names: Research programme: ZW-34 - Zymeworks

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator Zymeworks
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Jul 2016 Zymeworks plans to submit an IND application in Canada in 2016/2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top